Abbott Laboratories stock (US0028241000): valuation metrics in focus after recent gains

Abbott Laboratories shares continue to trade actively on the NYSE, with investors weighing the latest price levels and valuation metrics after a recent move higher. This article looks at the current quote, key multiples and how the healthcare group is positioned.

Abbott Laboratories shares remain in the spotlight on the New York Stock Exchange as investors digest the latest price action and valuation metrics following a recent upswing in the stock of the U.S. healthcare group.

According to Nasdaq as of 06/05/2026, Abbott Laboratories trades on the NYSE under the ticker ABT in U.S. dollars, reflecting its role as a large-cap healthcare and medical device company headquartered in the United States and forming part of the U.S. blue-chip universe, including the S&P 500 index.Nasdaq as of 06/05/2026

As a reference point for the recent move, GuruFocus reported that on 06/04/2026 Abbott Laboratories shares rose 4.4% to close at USD 90.78, moving within a documented 52-week trading range that frames current investor sentiment toward the stock.GuruFocus as of 06/04/2026

On European trading venues, the stock is also available to German retail investors via platforms such as Tradegate, where Abbott Laboratories is quoted in euros and can be accessed during extended trading hours alongside the primary U.S. listing.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare, medical devices and diagnostics
• Headquarters/country: Abbott Park, United States
• Core markets: North America, Europe, Asia-Pacific, Latin America
• Key revenue drivers: Medical devices, diagnostics, nutrition, established pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (ABT)
• Trading currency: USD

Abbott Laboratories: core business model

Abbott Laboratories focuses on developing and commercializing diagnostics, medical devices, nutrition products and established pharmaceuticals that are used in hospitals, laboratories and consumer healthcare settings around the world, with sales volumes driven by demand for chronic disease management, surgical procedures, routine testing and nutritional support.

Valuation metrics and multiples for Abbott Laboratories

For investors reviewing Abbott Laboratories on a valuation basis, current market data provide a snapshot of key multiples that frame how the stock is priced relative to its earnings and cash flows.

StockAnalysis reports that as of 06/05/2026, Abbott Laboratories traded at a share price of around USD 103.99 on the NYSE, implying a market capitalization in the large-cap range and placing the stock within the higher-priced segment of the global healthcare peer group at current levels.StockAnalysis as of 06/05/2026

The same StockAnalysis statistics page as of 06/05/2026 shows that Abbott Laboratories is valued on metrics such as the price-to-earnings ratio, enterprise-value-based multiples and dividend yield, which together give a more complete picture of the companys valuation than the headline share price alone, although investors should monitor how these figures evolve with each new earnings release and guidance update.StockAnalysis as of 06/05/2026

Beyond headline P/E levels, market participants often also consider metrics such as price-to-sales and price-to-book ratios, as reported by platforms like StockAnalysis as of 06/05/2026, to assess how Abbott Laboratories compares with other diversified healthcare companies across revenue and balance-sheet dimensions when screening for potential valuation discrepancies in the sector.StockAnalysis as of 06/05/2026

Dividend yield is another valuation component watched by income-oriented investors, and according to StockAnalysis as of 06/05/2026, Abbott Laboratories is listed with a forward dividend yield figure that reflects the combination of its regular quarterly distributions and the prevailing share price, although the precise yield will fluctuate with market movements and any future dividend declarations or increases made by the companys board.

For investors looking at enterprise-value-based measures, statistics pages such as those on StockAnalysis as of 06/05/2026 also compile ratios including EV/EBITDA and EV/Revenue for Abbott Laboratories, which can be useful when comparing capital-intensive healthcare and medical device businesses that may differ in leverage and depreciation profiles.

While platform data from sources like StockAnalysis provide a convenient overview, detailed valuation work on Abbott Laboratories typically involves connecting these multiples to the companys own reported earnings, cash flows and balance-sheet data in its quarterly and annual filings with the U.S. Securities and Exchange Commission, which are made available through the companys investor relations pages and EDGAR.

In the U.S. market context, Abbott Laboratories is frequently compared on valuation metrics with other large-cap healthcare and medical technology companies, with investors observing how its P/E, EV/EBITDA and dividend yield align with sector averages and whether its growth prospects justify any premium or discount implied by current market prices.

From a German retail-investor perspective, the valuation picture for Abbott Laboratories may also be viewed through the lens of euro-denominated trading on venues such as Tradegate or Xetra, where local pricing, liquidity conditions and currency effects relative to the U.S. dollar can influence the perceived attractiveness of the stock.

Conclusion

Abbott Laboratories continues to draw attention on its home market in the United States, with the NYSE listing and recent price levels providing a clear reference point for investors tracking the stock.

Data from GuruFocus as of 06/04/2026 and StockAnalysis as of 06/05/2026 illustrate both the recent move in the share price and the current valuation metrics, helping market participants situate Abbott Laboratories within the broader healthcare sector.

How those valuation indicators evolve alongside future earnings reports, guidance updates and sector developments will likely determine whether the stock remains aligned with, or diverges from, peers in the global medical devices and diagnostics space.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.